Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Rituximab Infusions Costlier When Given in the Hospital
Wayne Kuznar
Read More
Hematologists Urged to Reduce Unnecessary Tests/Procedures, and Costs to Improve Quality of Care
Caroline Helwick
Read More
Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs
Wayne Kuznar
Read More
Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants
Wayne Kuznar
Read More
Physicians Must Consider the Financial Burden of Allogeneic Transplants
Wayne Kuznar
Read More
Clinical Practice Guidelines Should Include Patient’s Preferences
Read More
FDA Approvals
Adverse Events Reporting in Oncology Studies Suboptimal
Read More
FDA Approvals
Ibrutinib Approved for Chronic Lymphocytic Leukemia
Read More
FDA Approvals
Tafinlar Receives Breakthrough Therapy Designation for Lung Cancer
Read More
Hematologists Often Ignore Treatment and Monitoring Recommendations
Caroline Helwick
Read More
1
2
3
4
Page 3 of 4
Results 21 - 30 of 32